Navigation Links
Tianyin Pharmaceutical Announces SFDA Approval to Market Azithromycin Dispersible Tablets

Company Receives Initial $3.7 Million Distribution Contract from Anhui

Huayuan Pharmaceutical Co., Ltd.

CHENGDU, China, March 17 /Xinhua-PRNewswire-FirstCall/ -- Tianyin Pharmaceutical, Co., Inc., (OTC Bulletin Board: TYNP), a manufacturer and supplier of modernized traditional Chinese medicine (''TCM'') based in Chengdu, China, today announced that the Company has been granted SFDA approval and is scheduled to launch Azithromycin Dispersible Tablets in the domestic market on April 15, 2008.

The manufacturing license for Azithromycin Dispersible Tablets is not only the first one Tianyin has received but also the first drug approval SFDA has granted to Sichuan Province in 2008. This is the third generic western medicine to be included in Tianyin's product portfolio. The Company will continue to diversify its TCM products, with additional western medicines as they receive approvals for the 10 drugs that are currently in the SFDA pipeline.

Azithromycin is highly effective in treating upper and lower respiratory tract infections and other bacterial infections in skins and reproductive system. Ever since the drug's first introduction, its sales have been growing steadily. Worldwide sales have grown from US$ 619 million in 1996 to $2.01 billion in 2003, representing a 32.6% growth over the previous year. Azithromycin has become a blockbuster product and is now among the TOP 50 prescription drugs in terms of global sales. It is estimated that approximately $350 million in total Azithromycin sales were generated in China during 2007.

''We are pleased to have the first of our pipeline products approved by the SFDA and believe that the launch of Azithromycin provides the opportunity for significant growth in both sales revenue and net profit in the coming years,'' stated Dr. Guoqing Jiang, Chairman and CEO.

The largest domestic distributor of Azithromycin, Anhui Huayuan Pharmaceutical Co., Ltd. is currently one of Tianyin's top strategic partners and has awarded the Company a $3.66 million distribution contract for 2008 covering most of the PRC for Azithromycin and other products. Margins associated with this product are in line with the Company's blended average during the past year. This collaboration will help speed the market entry of Tianyin's Azithromycin Dispersible Tablets and enable the Company to leverage its National SFDA manufacturing approval to gain market share throughout China.

About Tianyin Pharmaceuticals

Tianyin is a manufacturer and supplier of modernized Traditional Chinese Medicine ("TCM") in China. It was established in 1994 and acquired by the current management team in August 2003. It has a comprehensive product portfolio of 34 modernized TCMs in the market, 22 of which are listed in the highly selective National Medicine Catalog of the National Medical Insurance Program. Tianyin owns and operates two GMP manufacturing facilities and an R&D platform supported by leading Chinese academic institutions. The Company has a pipeline of 51 pharmaceutical products pending approval. Tianyin has an extensive nationwide distribution network throughout China with a sales force of 523 salespeople. Tianyin is headquartered in Chengdu, Sichuan Province with two manufacturing facilities and a total of 869 employees. Tianyin achieved revenue of $20.4 million and net income of $3.95 million in FY2007 ending June 30, 2007.

Safe Harbor Statement

The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

For more information, please contact:

For the Company:

Allen Tang, Ph.D., MBA, Assistant to the CEO


Tel: +86-15821225642



HC International, Inc.

Alan Sheinwald

Tel: +1-914-669-0222 (U.S.)


SOURCE Tianyin Pharmaceutical, Co., Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Tianyin Pharmaceutical, Inc. to Host 2008 Second Quarter Earnings Conference Call on Thursday, February 14, 2008 at 4:15 p.m. EST
2. Tianyin Pharmaceutical Co., Inc. Announces Second Quarter 2008 Financial Results
3. Tianyin Pharmaceutical Appoints Three New Independent Board Members
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
9. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
Post Your Comments:
(Date:11/24/2015)... , Nov. 24, 2015  Twist Bioscience, a ... Emily Leproust, Ph.D., Twist Bioscience chief executive officer, ... Conference on December 1, 2015 at 3:10 p.m. ... York City. --> ... . Twist Bioscience is on Twitter. Sign up ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... OrthoAccel® Technologies, Inc., on being named to Deloitte's 2015 Technology Fast 500 list ... facility, OrthoAccel manufactures AcceleDent®, a FDA-cleared, Class II medical device that speeds up ...
(Date:11/24/2015)... CHARLOTTESVILLE, Va. , Nov. 24, 2015 /PRNewswire/ ... company focused on discovering drugs for metabolic disorders, ... Watkins to its Board of Directors (BOD). ... executive officer of Human Genome Sciences (HGS), and ... Industry Organization. Jim Powers , Chairman ...
(Date:11/24/2015)... ... November 24, 2015 , ... Whitehouse Laboratories is pleased ... The new stand-alone facility will be strictly dedicated to basic USP 61, USP 62 ... clients the chance to have complete chemistry and micro testing performed by one supplier. ...
Breaking Biology Technology:
(Date:11/12/2015)... golden retriever that stayed healthy despite having the gene ... new lead for treating this muscle-wasting disorder, report scientists ... and Harvard and the University of São Paolo in ... pinpoints a protective gene that boosts muscle regeneration, ... Children,s lab of Lou Kunkel , PhD, is ...
(Date:11/12/2015)... 2015   Growing need for low-cost, easy ... been paving the way for use of biochemical ... analytes in clinical, agricultural, environmental, food and defense ... in medical applications, however, their adoption is increasing ... continuous emphasis on improving product quality and growing ...
(Date:11/10/2015)... , Nov. 10, 2015  In this ... the basis of product, type, application, disease ... in this report are consumables, services, software. ... are safety biomarkers, efficacy biomarkers, and validation ... report are diagnostics development, drug discovery and ...
Breaking Biology News(10 mins):